Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
Evolution of care quality metrics for chronic hepatitis B in the hepatitis C direct-acting antiviral era — David Kaplan (2020) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Evolution of care quality metrics for chronic hepatitis B in the hepatitis C direct-acting antiviral era
DK
Shared by
David Kaplan
Evolution of care quality metrics for chronic hepatitis B in the hepatitis C direct-acting antiviral era
Article
2020
en
Authors
DK
David Kaplan
MS
Marina Serper
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2017
Current therapy for chronic hepatitis C: The role of direct-acting antivirals
Guangdi Li
,
De Clercq Erik
Article
2022
Macroeconomic assessment of overall and per-patient healthcare costs of Hepatitis C-infected patients in an integrated health system in the era of direct-acting antiviral therapy
David Kaplan
,
Claire Durkin
,
Marina Serper
Article
2017
Unique Characteristics Associated with Sustained Liver Damage in Chronic Hepatitis C Patients Treated with Direct Acting Antivirals
Masashi Kono
,
Naoshi Nishida
,
Satoru Hagiwara
,
Tomohiro Minami
,
Hirokazu Chishina
,
Tadaaki Arizumi
,
Kosuke Minaga
,
Ken Kamata
,
Yoriaki Komeda
,
Toshiharu Sakurai
,
Mamoru Takenaka
,
Masahiro Takita
,
Norihisa Yada
,
Hiroshi Ida
,
Yasunori Minami
,
Kazuomi Ueshima
,
Tomohiro Watanabe
,
Masatoshi Kudo
Article
2010
Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections
De Clercq Erik
,
Geoffrey Férir
,
Suzanne J. F. Kaptein
,
Johan Neyts
Article
2021
The Association Between Chronic Hepatitis B, Chronic Hepatitis C, Sustained Liver Damage, and Features of Increased Cardiovascular Risk
Jacek Czepiel
,
Marek Rajzer
,
Grzegorz Bilo
,
Gianfranco Parati
,
Grażyna Biesiada
,
Dorota Cibor
,
E. Pitera
,
Paweł Wołkow
,
Mateusz Michalak
,
Aleksander Garlicki
Discussion(0)
No comments yet. Be the first to comment.